Transient myeloproliferative disordes in a newborns with Down Syndrome

We emphasize the importance of the peripheral blood smear examination in newborns with DS, especially with hepatosplenomegaly, leukocytosis or throm¬bocytopenia and myeloblast of the peripheral smear, in order to diagnose TMD.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Transient myeloproliferative disease TMD , defined by circulating nonlymphoid blast in the peripheral blood, occurs in approximately 10% of infants with constitutional trisomy 21 Down syndrome .

📊

Key Findings & Data:The TMD phenotype may also occur in newborns who do not have clinical signs of Down syndrome but nonconstitutional trisomy 21 due to mosaicism.

💡

Conclusion & Impact:We emphasize the importance of the peripheral blood smear examination in newborns with DS, especially with hepatosplenomegaly, leukocytosis or throm¬bocytopenia and myeloblast of the peripheral smear, in order to diagnose TMD.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Down sendromu · yenidoğan · geçici myeloproliferatif hastalık

Abstract

Transient myeloproliferative disease TMD , defined by circulating nonlymphoid blast in the peripheral blood, occurs in approximately 10% of infants with constitutional trisomy 21 Down syndrome . The TMD phenotype may also occur in newborns who do not have clinical signs of Down syndrome but nonconstitutional trisomy 21 due to mosaicism. Acute mega-karyoblastic leukemia AML-M7 develops in approxima¬tely 30 % of the cases with TMD within the first three years of life. In this case report, a newborn with TMD with Down syndrome is presented. We emphasize the importance of the peripheral blood smear examination in newborns with DS, especially with hepatosplenomegaly, leukocytosis or throm¬bocytopenia and myeloblast of the peripheral smear, in order to diagnose TMD.

Özet

Geçici myeloproliferatif hastalık GMPH , Trizomi 21 Down Sendromu tanısı ile izlenen infantların yaklaşık %10’unda ortaya çıkabilen, periferik kanda myeloid blastların artımı ile karakterize bir durumdur. GMPH, Down Sendromun’nun işaretlerini taşımayan mozaik trizomi 21 hastalarında da görülebilir. GMPH’lı infantlarda ilk 3 yılda akut mega¬karyoblastik lösemi AML-M7 gelişme riski yaklaşık % 30’dur. Biz burada GMPH gelişen Down Sendromlu bir vaka sunduk. Down sendromlu yenidoğanlarda hepasopslenomegali, lökositoz veya trombositopeni ve periferik kan yayma incelemeside myeloblast saptanması durumunda GMPH düşünülmesinin önemine vurgu yapmak istedik

Keywords

Down sendromu yenidoğan geçici myeloproliferatif hastalık Down Syndrome newborn transient myeloproliferative disease

🔖

Cite This Article

BEKDAŞ, M., ALTUNHAN, H., DEMİRCİOĞLU, F., KISMET, E., GÖKSÜGÜR, S. B., YEŞİLLER, E., SARAÇ, E. G. (2022). Transient myeloproliferative disordes in a newborns with Down Syndrome. Abant Tıp Dergisi, Cilt: 2 - Sayı: 1, 46–49. https://ajindex.com/articles/427219

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (7)

Roy A, Roberts I, Vyas P. Biology and manage- ment of transient abnormal myelopoiesis (TAM) in children with Down syndrome. Semin Fetal Neonatal Med. 2012;17:196-201.
Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, Pekrun A, Macakova-Reinhardt K, Reinhardt D. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008;111:2991- 8. Massey GV, Zipursky A, Chang MN, Doyle JJ, Na- sim S, Taub JW, Ravindranath Y, Dahl G, Weins- tein HJ; A prospective study of the natural his- tory of transient leukemia (TL) in neonates with Down syndrome (DS): children’s Oncology Group (COG) study POG-9481. Blood 2006;107: 4606-13. GH Judih: Chromosomal Clinical Abnormalities, In: Richar E. Behrman, Robert M. Kliegman, Hall B. Jenson (Eds), Nelson Textbook of Pediatrics. 17th edition. Saunders an Imprint of Elsevier Science, USA, 2004: 382-91.
Bessler M, Mason JP,Link DC, Wilson DB: Inheri- ted Bone Marrow Syndromes, In: Stuart H. Or- kin, David G. Nathan, David Ginsburg, A. Tho- mas Look, David E. Fisher, Samuel E. Lux (Eds), Nathan and Oski’s Hematology of Infancy and Childhood. 7th edition. Saunders an Imprint of Elsevier Science, USA,2009: 307-95. Lange B. The management of neoplastic disor- ders of haematopoiesis in children with Down’s syndrome. Br J Haematol. 2000;110(3):512- 524. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355:165-69.
Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, Sharma M, Loew TW, Arceci RJ, Bar- nard D, Doyle J, Massey G, Perentesis J, Ravind- ranath Y, Taub J, Smith FO. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a re- port from the Children’s Oncology Group Study A2971. Blood 2011;118:6752-9.
Smrcek JM, Baschat AA, Germer U, Gloeckner- Hofmann K, Embruch U. Fetal hydrops and he- patosplenomegaly in the second half of preg- nancy: a sign of myeloproliferative disorder in fetuses with trisomy 21. Ultrasound Obstet Gy- necol 2001;17:403-9.
Groet J, McElwaine S, Spinelli M, Rinaldi A, Burtscher I, Mulligan C, Mensah A, Cavani S, Dagna-Bricarelli F, Basso G, Cotter FE, Nizetic D. Acquired mutations in GATA1 in neonates with Down’s syndrome with transient myeloid disor- der. Lancet 2003;361:1617-20.
Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, Amariglio N, Biondi A, Muler I, Rechavi G, Kempski H, Haas OA, Izraeli S. Mut